Table 3 Multivariate analysis results for over 65% and 90% volume reduction at MRI evaluation
Over 65% volume reduction | Over 65% volume reduction | Over 90% volume reduction | Over 90% volume reduction | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OR | (95% CI) | p-value | VIF | OR | (95% CI) | p-value | VIF | OR | (95% CI) | p-value | VIF | OR | (95% CI) | p-value | VIF | ||
GTV dose | D80 < 42 Gy | 1 | < 0.01 | 1.03 | 1 | < 0.01 | 1.05 | ||||||||||
D80 > 42 Gy | 3.68 | (1.85–7.34) | 4.70 | (2.31–9.56) | |||||||||||||
GTV dose | D98 < 39 Gy | 1 | < 0.01 | 1.03 | 1 | < 0.01 | 1.06 | ||||||||||
D98 > 39 Gy | 4.68 | (2.29–9.56) | 6.41 | (2.91–14.15) | |||||||||||||
Age (years) | 22–65 | 1 | 0.01 | 1.04 | 1 | 0.01 | 1.03 | 1 | 0.06 | 1.05 | 1 | 0.05 | 1.05 | ||||
> 65 | 0.45 | (0.24–0.85) | 0.43 | (0.23–0.83) | 0.58 | (0.33–1.02) | 0.57 | (0.32–1.00) | |||||||||
Primary cancer | Lung and Breast | 1 | 0.02 | 1.04 | 1 | 0.01 | 1.05 | ||||||||||
Others | 0.46 | (0.24–0.88) | 0.42 | (0.22–0.81) | |||||||||||||
Time for MRI evaluation | 5–6.5 months | 1 | 0.08 | 1.01 | 1 | 0.14 | 1.01 | 1 | < 0.01 | 1.02 | 1 | 0.02 | 1.02 | ||||
6.5–8.5 months | 1.78 | (0.93–3.42) | 1.64 | (0.85–3.16) | 2.16 | (1.23–3.80) | 2.02 | (1.14–3.56) | |||||||||